Company Interview / AVITA’s turnaround finds its footing

Key points:

Guidance set at US$80–85m with targeted ~20% growth and pathway to profitabilityFocus on expanding RECELL, Cohealyx and PermeaDerm across existing and new marketsEarly-stage European rollout adds to presence in US, Japan, Australia and New Zealand

Cary Vance from AVITA Medical outlines a turnaround under way at the wound care specialist, highlighting recovering growth after last year’s US reimbursement challenges. Vance states that most reimbursement issues are now resolved, with the company guiding to US$80–85 million in revenue for the year and targeting around 20% growth at the top end of that range. He indicates that crossing a certain quarterly revenue threshold is expected to push AVITA into cash flow positive territory, with profitability anticipated next year.

Vance highlights the flagship RECELL system, which he says is only about 20% penetrated in its addressable market. The strategy, in his view, focuses on deeper penetration in existing US accounts, while adding two newer products: the Cohealyx dermal matrix and a biosynthetic dressing, PermeaDerm. He cites very strong clinical data for Cohealyx , claiming it can prepare wound beds for grafting roughly 20 days faster than competing products, which he argues is highly valued by clinicians.

Global expansion is another priority, with Vance pointing to operations in the US, Japan, Australia, New Zealand and early-stage entry into several European markets. He sees AVITA’s portfolio as well placed to support a continuum of wound care products and underlines a significant, underpenetrated total addressable market.